170 related articles for article (PubMed ID: 33442293)
1. The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand-Foot Skin Reaction.
Shou L; Shao T; Zhao F; Chen S; Chen Q; Shu Q
Cancer Manag Res; 2021; 13():45-53. PubMed ID: 33442293
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Safety of the Shouzu Ning Decoction Treatment Versus Halometasone Plus Celecoxib Treatment in Patients With Grade 2 HFSR: A Randomized Clinical Trial.
Shou L; Shao T; Chen J; Zhang Y; Shu Q
Integr Cancer Ther; 2023; 22():15347354231168796. PubMed ID: 37082777
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study.
Shou L; Chen J; Shao T; Zhang Y; Zhao S; Chen S; Shu Q
Support Care Cancer; 2023 Jun; 31(7):375. PubMed ID: 37273007
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.
Zhu Y; Zhang X; Lou X; Chen M; Luo P; He Q
Clin Exp Pharmacol Physiol; 2018 Jul; 45(7):659-667. PubMed ID: 29543385
[TBL] [Abstract][Full Text] [Related]
5. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
Anderson R; Jatoi A; Robert C; Wood LS; Keating KN; Lacouture ME
Oncologist; 2009 Mar; 14(3):291-302. PubMed ID: 19276294
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial.
Nishizawa A; Shinozaki E; Wakatsuki T; Satoh T; Yamazaki N; Oyamada S; Ariyoshi K; Kihara K; Tsuboi M; Yamaguchi K
BMC Cancer; 2023 May; 23(1):401. PubMed ID: 37142953
[TBL] [Abstract][Full Text] [Related]
7. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
8. [Association between hand-foot skin reaction and effectiveness of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma].
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Yihebali C; Zhou AP; Wang JW; Sun Y
Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(34):2717-2721. PubMed ID: 27667104
[No Abstract] [Full Text] [Related]
9. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
Melosky BL; Lim HJ; Davies JM; Gill S; Kollmannsberger CK; Ho MY; Vandt SA; Renouf DJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):411-417. PubMed ID: 30535909
[TBL] [Abstract][Full Text] [Related]
11. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
[TBL] [Abstract][Full Text] [Related]
13. Clinical study for external Chinese herbal medicine LC09 treating hand-foot skin reaction associated with the antitumor targeted drugs: Protocol for a prospective, randomized, controlled, double-blind, and monocentric clinical trial.
Wang G; Jia L; Pei Y; Yu R; Gao Y; Deng C; Lou Y
Medicine (Baltimore); 2020 Jan; 99(4):e18849. PubMed ID: 31977883
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
15. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Belum VR; Wu S; Lacouture ME
Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
[TBL] [Abstract][Full Text] [Related]
16. Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.
Chanprapaph K; Rutnin S; Vachiramon V
Am J Clin Dermatol; 2016 Aug; 17(4):387-402. PubMed ID: 27221667
[TBL] [Abstract][Full Text] [Related]
17. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Jatoi A; Ou FS; Ahn DH; Zemla TJ; Le-Rademacher JG; Boland P; Ciombor KK; Jacobs NL; Pasche B; Cleary JM; McCune JS; Pedersen KS; Barzi A; Chiorean EG; Heying EN; Lenz HJ; Sloan JA; Grothey A; Lacouture ME; Bekaii-Saab T
Oncologist; 2021 Jul; 26(7):610-618. PubMed ID: 33604969
[TBL] [Abstract][Full Text] [Related]
18. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
Li J; Gu J
Crit Rev Oncol Hematol; 2017 Nov; 119():50-58. PubMed ID: 29065985
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
20. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]